A PILOT STUDY OF PENTOXIFYLLINE IN REDUCING SYSTEMIC INFLAMMATION AND IMPROVING

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项前瞻性、单中心、单臂、开放标签的初步研究，评估己酮可可碱(PTX)的潜在疗效和安全性，已酮可可碱是一种磷酸二酯酶抑制剂，可阻断肿瘤坏死因子？(肿瘤坏死因子？)，用于治疗12例HIV感染者的内皮功能障碍，这些患者在印第安纳大学医学中心看到，CD_4细胞计数超过350个/？L，目前未接受抗逆转录病毒治疗。登记的受试者将在基线以及PTX治疗4周和8周后再次测量他们的臂部血流介导的扩张(FMD)，这是一种衡量内皮功能的指标，以及其他心血管和免疫学参数。每个单独的受试者将被跟踪大约10周。这项研究的总期限约为8个月。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a prospective, single center, single arm, open-label, pilot study evaluating the potential efficacy and safety of pentoxifylline (PTX), a phosphodiesterase inhibitor that blocks tumor necrosis factor-? (TNF-?), in the treatment of endothelial dysfunction in twelve HIV-infected patients seen at the Indiana University Medical Center with CD4 cell counts greater than 350/¿L and not currently receiving antiretroviral therapy. Enrolled subjects will have their brachial flow-mediated dilation (FMD), a measure of endothelial function, and other cardiovascular and immunologic parameters measured at baseline and again after 4 and 8 weeks of treatment with PTX. Each individual subject will be followed for approximately 10 weeks. The total duration of this study will be approximately 8 months.